Accounting for Innovation
Revenue Recognition In The Age of Biotech Breakthroughs
By Michelle Olufeso-Nwokobia | Publisher: MIO Publishing Ltd
About the book
Licensing deals are the engine of value creation in pharma and biotech. They are also where revenue recognition goes wrong most often, and most expensively.
Written by Michelle Olufeso-Nwokobia, co-developer of IFRS 15 and former representative of a major pharmaceutical company at the IASB and FASB, this book addresses the specific challenges that IFRS 15 creates for pharma, diagnostics, and biotech licensing, not in the abstract, but deal by deal, obligation by obligation.
Readers will learn how to identify and separate performance obligations in complex multi-year collaborations, handle variable consideration when milestone payments depend on clinical outcomes, distinguish right-to-use from right-to-access licences and understand why that distinction determines revenue timing, and navigate the divergences between IFRS 15 and US GAAP ASC 606 that matter for globally active companies.
This is a practitioner's guide, not a textbook. Every chapter is grounded in how these deals are actually structured and what finance functions are actually asked to account for. Essential reading for CFOs, heads of technical accounting, business development executives, and anyone who negotiates or accounts for pharma and biotech licensing arrangements.
Editions of Accounting for Innovation
- Hardcover
- ISBN 9781066663606
- Paperback
- ISBN 9781066663644
- EBook
- ISBN 9781066663620
- PDF
- ISBN 9781066663613
- Audiobook
- ISBN 9781066663637
Read an Excerpt
Licensing deals are the engine of value creation in pharma and biotech. They are also where revenue recognition goes wrong most often, and most expensively.
Written by Michelle Olufeso-Nwokobia, co-developer of IFRS 15 and former representative of a major pharmaceutical company at the IASB and FASB, this book addresses the specific challenges that IFRS 15 creates for pharma, diagnostics, and biotech licensing, not in the abstract, but deal by deal, obligation by obligation.
Readers will learn how to identify and separate performance obligations in complex multi-year collaborations, handle variable consideration when milestone payments depend on clinical outcomes, distinguish right-to-use from right-to-access licences and understand why that distinction determines revenue timing, and navigate the divergences between IFRS 15 and US GAAP ASC 606 that matter for globally active companies.
This is a practitioner's guide, not a textbook. Every chapter is grounded in how these deals are actually structured and what finance functions are actually asked to account for. Essential reading for CFOs, heads of technical accounting, business development executives, and anyone who negotiates or accounts for pharma and biotech licensing arrangements.
Frequently Asked Questions
What is Accounting for Innovation about?
Licensing deals are the engine of value creation in pharma and biotech. They are also where revenue recognition goes wrong most often, and most expensively.
Written by Michelle Olufeso-Nwokobia, co-developer of IFRS 15 and former representative of a major pharmaceutical company at the IASB and FASB, this book addresses the specific challenges that IFRS 15 creates for pharma, diagnostics, and biotech licensing, not in the abstract, but deal by deal, obligation by obligation.
Readers will learn how to identify and separate performance obligations in complex multi-year collaborations, handle variable consideration when milestone payments depend on clinical outcomes, distinguish right-to-use from right-to-access licences and understand why that distinction determines revenue timing, and navigate the divergences between IFRS 15 and US GAAP ASC 606 that matter for globally active companies.
This is a practitioner's guide, not a textbook. Every chapter is grounded in how these deals are actually structured and what finance functions are actually asked to account for. Essential reading for CFOs, heads of technical accounting, business development executives, and anyone who negotiates or accounts for pharma and biotech licensing arrangements.
What core themes, tropes, or subjects are explored in Accounting for Innovation?
Economics, Finance, Business and Management > Finance and accounting > Accounting
Where can I read a sample of Accounting for Innovation?
You can read an official preview of the few pages here https://www.book2look.com/book/9781066663606
How long is Accounting for Innovation and how many pages does it have?
Accounting for Innovation has 202 page(s)
Who is/are the Author/s of the book Accounting for Innovation?
Michelle Olufeso-Nwokobia
What are the ISBN numbers for the physical and digital editions?
Accounting for Innovation is available as hardcover(ISBN 9781066663606) and paperback(ISBN 9781066663644) and ebook(ISBN 9781066663620) and pdf(ISBN 9781066663613) and audiobook(ISBN 9781066663637)
Where can I buy Accounting for Innovation online or support local independent bookshops?
You can buy Accounting for Innovation from below
Where can I buy Accounting for Innovation?